DE-117

DRUG3 trials

Sponsors

Santen Inc., Santen Pharmaceutical Co., Ltd.

Conditions

Glaucoma and Ocular HypertensionHealthy Male AdultsOpen Angle Glaucoma or Ocular Hypertension

Phase 1

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

CompletedNCT01654484

Santen Inc.Glaucoma and Ocular Hypertension

Start: 2012-07-31End: 2012-11-30Updated: 2018-04-18

A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -

CompletedNCT02650063

Santen Pharmaceutical Co., Ltd.Healthy Male Adults

Start: 2015-12-31End: 2016-03-31Updated: 2016-06-29

Phase 3

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

CompletedNCT02981446

Santen Pharmaceutical Co., Ltd.Open Angle Glaucoma or Ocular Hypertension

Start: 2017-01-31End: 2019-01-31Updated: 2024-03-15

Related Papers

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial.

2024-07-164 citations